https://www.live-feeds.com/feed/fda-scientists-opposed-the-trump-administration-s-effort-to-ease-peptides-accessContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/fda-scientists-opposed-the-trump-administration-s-effort-to-ease-peptides-accesshttps://www.live-feeds.com/feed/fda-scientists-opposed-the-trump-administration-s-effort-to-ease-peptides-access#u165634Sat, 31 Oct 2026 11:11:11 +0000Food and Drug Administration scientific staff members opposed an administration effort to ease access to unproven peptide drugs, according to six people familiar with the development. The policy, favored by Health Secretary Robert F. Kennedy Jr., allows for the compounding of certain unapproved peptides, including products like BPC-157 and TB-500. Sources indicated that FDA scientific personnel had limited input in drafting the policy before the Department of Health and Human Services moved forward to permit the broader availability of these substances.Why it mattersThe disagreement highlights